Cargando…

Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib

BACKGROUND: Previous studies have confirmed that preoperative nutritional-inflammatory indicators can predict prognosis in various malignancies. However, to the best of our knowledge, no study has investigated the assessment of systemic inflammatory immunity index (SII) combined with prognostic nutr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Ping’an, Wu, Jiaxiang, Wu, Haotian, Sun, Chenyu, Guo, Honghai, Lowe, Scott, Yang, Peigang, Tian, Yuan, Liu, Yang, Meng, Lingjiao, Zhao, Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869595/ https://www.ncbi.nlm.nih.gov/pubmed/36690935 http://dx.doi.org/10.1186/s12876-023-02658-x

Ejemplares similares

Sarcopenia: Molecular regulatory network for loss of muscle mass and function
por: Wu, Jiaxiang, et al.
Publicado: (2023)

Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST
por: Ding, Ping’an, et al.
Publicado: (2022)

Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
por: Ding, Ping’an, et al.
Publicado: (2022)

Comment on: ‘Triceps skinfold‐albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al.
por: Ding, Ping'an, et al.
Publicado: (2023)

Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer
por: Lv, Jingxia, et al.
Publicado: (2023)

Comment on 'Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer' by Xie et al.
por: Ding, Ping'an, et al.
Publicado: (2023)

Relationship Between Nutritional Status and Clinical Outcome in Patients With Gastrointestinal Stromal Tumor After Surgical Resection
por: Ding, Ping'an, et al.
Publicado: (2022)

Predictive Effect of Systemic Immune-Inflammation Index Combined With Prognostic Nutrition Index Score on Efficacy and Prognosis of Neoadjuvant Intraperitoneal and Systemic Paclitaxel Combined With Apatinib Conversion Therapy in Gastric Cancer Patients With Positive Peritoneal Lavage Cytology: A Prospective Study
por: Ding, Ping’an, et al.
Publicado: (2022)

Phase angle derived from bioelectrical impedance analysis as a marker for predicting sarcopenia
por: Wu, Haotian, et al.
Publicado: (2022)

Association Between the Nutritional Risk and the Survival Rate in Newly Diagnosed GIST Patients
por: Ding, Ping'an, et al.
Publicado: (2021)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study
por: Ding, Ping’an, et al.
Publicado: (2022)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
por: Kurokawa, Yukinori, et al.
Publicado: (2017)

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
por: Wang, Shang-Yu, et al.
Publicado: (2019)

Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
por: Zhao, Wen-Yi, et al.
Publicado: (2014)

Combined systemic inflammatory immunity index and prognostic nutritional index scores as a screening marker for sarcopenia in patients with locally advanced gastric cancer
por: Ding, Ping'an, et al.
Publicado: (2022)

Clinicopathologic change of gastrointestinal stromal tumor after neoadjuvant imatinib followed by surgical resection
por: Kang, Gil Ho, et al.
Publicado: (2012)

GASTROINTESTINAL STROMAL TUMOR OF THE RECTUM TREATED WITH NEOADJUVANT IMATINIB FOLLOWED BY TRANSANAL ENDOSCOPIC MICROSURGERY
por: NAHAS, Caio Sergio Rizkallah, et al.
Publicado: (2015)

Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies
por: Hedenström, Per, et al.
Publicado: (2017)

Impact of skeletal muscle loss during conversion therapy on clinical outcomes in lavage cytology positive patients with gastric cancer
por: Ding, Ping’an, et al.
Publicado: (2022)

Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
por: Yoon, Kyu Jong, et al.
Publicado: (2011)

AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis
por: Li, Chien-Feng, et al.
Publicado: (2014)

Neoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal stromal tumor of the rectum
por: Kyo, Kennoki, et al.
Publicado: (2016)

Laparoscopic resection of locally advanced gastrointestinal stromal tumour (GIST) of the stomach following neoadjuvant imatinib chemoreduction
por: Berney, Christophe R.
Publicado: (2015)

Gastric volvulus associated with shrinkage of a gastrointestinal stromal tumor by neoadjuvant imatinib: a case report
por: Sugiyama, Yoichi, et al.
Publicado: (2023)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Functional properties of circular RNAs and research progress in gastric cancer
por: Ding, Ping’an, et al.
Publicado: (2022)

Complete laparoscopic wedge resection of a giant locally advanced gastric GIST with near pathological complete response after preoperative treatment with imatinib mesylate: A case report
por: Guo, Honghai, et al.
Publicado: (2021)

Lymphangiogenesis in gastric cancer: function and mechanism
por: Liu, Pengpeng, et al.
Publicado: (2023)

Assessment of Systemic Inflammation and Nutritional Indicators in Predicting Recurrence-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors
por: Lu, Zhenhua, et al.
Publicado: (2021)

Downstaging of a Rectal Gastrointestinal Stromal Tumor by Neoadjuvant Imatinib Therapy Allowing for a Conservative Surgical Approach
por: dos Santos Fernandes, Gustavo, et al.
Publicado: (2009)

A large esophageal gastrointestinal stromal tumor that was successfully resected after neoadjuvant imatinib treatment: case report
por: Yanagawa, Senichiro, et al.
Publicado: (2014)

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)
por: Alassani, Fousséni, et al.
Publicado: (2019)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Comparison of short-term efficacy and safety between total robotic and total 3D laparoscopic distal radical gastrectomy for gastric cancer in Enhanced Recovery After Surgery (ERAS) protocol: a propensity score matching study
por: Tian, Yuan, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study
por: Li, Weihao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t44shnm58g0cs6k3jc08o48b0f